Medicine or supplement? The classification question that decides your European launch
The same formula can be a medicinal product in one market and a food supplement in another — and the classification must be settled before packaging starts.
Insights
Regulatory & market notes.
Practical notes on European market access, regulatory routes and pharmacy commercialisation — written by the team that runs it operationally.
-
Switzerland first, or Germany first? Sequencing a DACH launch
Market size is the wrong first criterion. Regulatory route, pharmacy channel structure and pricing reference effects usually decide the better entry order.
-
What a GDP-compliant distribution chain actually requires
Temperature control is the part everyone knows. Qualification, documentation and recall readiness are where audits are lost.
-
Health claims: the four sentences you are allowed to write
Under the EU Claims Regulation most marketing copy for supplements is not defensible. A practical framework for compliant messaging.
-
Getting listed: how pharmacy wholesalers evaluate a new product
Margins, pack sizes, PZN registration and rotation expectations — the criteria behind a listing decision.
-
Licensing, distribution or full market access — choosing the model
Four partnership structures, what each demands of you operationally, and when the leanest option stops being the cheapest.
Working on a launch?
Discuss your product with the team.
Product, target markets, timeline — you get a clear next step.